An overview of clinical and preclinical research in Malignant Pleural Mesothelioma, highlighting major companies involved, therapeutic evaluations, upcoming treatments, treatment strategies
Malignant Pleural Mesothelioma Pipeline constitutes 20+ key companies continuously working towards developing 20+ Malignant Pleural Mesothelioma treatment therapies, analyzes DelveInsight.
Malignant Pleural Mesothelioma Overview:
Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the lining of the lungs. It is most often associated with past exposure to asbestos, with a latency period of approximately 40 years between exposure and the development of the disease. The global incidence of MPM has been gradually rising over the last decade and is expected to peak around 2020. The outlook for MPM is generally poor, with median survival rates ranging from 8 to 14 months post-diagnosis. Women tend to have a slightly better prognosis than men, but since the disease is largely occupational, it is more prevalent in men, with a male-to-female ratio of 4:1. MPM is classified into four main histological subtypes: epithelioid, sarcomatoid, biphasic (mixed), and desmoplastic. Asbestos exposure, often occurring over 40 years ago, is the primary cause of most cases, though other factors include exposure to erionite (a mineral found in Turkey), chest wall radiation, and the simian virus.
Download malignant pleural mesothelioma pipeline insights report @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
“Malignant Pleural Mesothelioma Pipeline Insight 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Pleural Mesothelioma Therapeutics Market.
Key Takeaways from the Malignant Pleural Mesothelioma Pipeline Report
-
DelveInsight’s Malignant Pleural Mesothelioma (MPM) pipeline report highlights a dynamic landscape with over 20 active companies developing more than 20 potential therapies for the treatment of MPM.
-
In September 2024, the FDA approved Merck’s KEYTRUDA® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic MPM.
-
Key players in the MPM space, including MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd., AGC Biologics S.p.A., Aduro Biotech, Inc., Novartis, Bristol-Myers Squibb, TCR2 Therapeutics, Novotech (Australia) Pty Limited, AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others, are actively researching and developing new treatments to improve the current MPM therapeutic options.
-
Notable pipeline therapies showing promise in various stages of development include Semaglutide, ACP 01, Revacept, among others.
Malignant Pleural Mesothelioma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Malignant Pleural Mesothelioma Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Malignant Pleural Mesothelioma market.
Request for a detailed informative report on malignant plural mesothelioma pipeline insights
Malignant Pleural Mesothelioma Emerging Drugs
-
NGR-TNF: MolMed
-
Pembrolizumab : Merck & Co
-
Pegargiminase: Polaris Pharmaceuticals
-
Lurbinectedin: PharmaMar
-
YS110: Ys Therapeutics
Malignant Pleural Mesothelioma Companies
Over 20 major companies are working on developing therapies for Malignant Pleural Mesothelioma. Among them, MolMed has drug candidates for the condition in the most advanced stage, specifically Phase III.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Malignant Pleural Mesothelioma Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Malignant Pleural Mesothelioma Therapies and Key Companies: Malignant Pleural Mesothelioma Clinical Trials and advancements
Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment
• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type
Download Malignant Pleural Mesothelioma Sample report to know in detail about the Malignant Pleural Mesothelioma treatment market @ Malignant Pleural Mesothelioma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Malignant Pleural Mesothelioma Current Treatment Patterns
4. Malignant Pleural Mesothelioma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Malignant Pleural Mesothelioma Late-Stage Products (Phase-III)
7. Malignant Pleural Mesothelioma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Malignant Pleural Mesothelioma Discontinued Products
13. Malignant Pleural Mesothelioma Product Profiles
14. Malignant Pleural Mesothelioma Key Companies
15. Malignant Pleural Mesothelioma Key Products
16. Dormant and Discontinued Products
17. Malignant Pleural Mesothelioma Unmet Needs
18. Malignant Pleural Mesothelioma Future Perspectives
19. Malignant Pleural Mesothelioma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Malignant Pleural Mesothelioma Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
